ArticlemBio2024
Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive vulvovaginal candidiasis pathogenesis.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 27 citations in OpenAlex.
- Dangerous liaisons: Candidalysin and myeloid cells in candidiasis.PLoS pathogens · 2026Article
- Cytokine signalling in vaginal epithelial cells: mechanistic insights into epithelial immunity and inflammatory milieu in vulvovaginal candidiasis.European cytokine network · 2026Review
- Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses.Nature communications · 2026Article
- An In Vitro A-431 Epithelial Cell Infection Model for Studying Fungal Pathogenicity and Immune Responses Associated With Vulvovaginal Candidiasis.Bio-protocol · 2026Article
- An IL-1, IL-17, and IL-22 cytokine circuit controls vulvovaginal candidiasis independently of estrogen.PLoS pathogens · 2026Article
- DNAM-1 mediates NK-cell activation and host-pathogen interaction via direct binding to fungal cell wall proteases.Communications biology · 2026Article
- Hemolytic Activity of VaginalPathogens (Basel, Switzerland) · 2026Article
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Article
- Article
- Candidalysin at the epithelial-systemic interface: mechanistic evidence, critical-care relevance, and translational opportunities in invasive candidiasis.Frontiers in cellular and infection microbiology · 2026Review
- Commensal colonization ofMicrobiology spectrum · 2025Article
- Commensalism and pathogenesis of Candida albicans at the mucosal interface.Nature reviews. Microbiology · 2025Review
- Complex-mediated evasion: modeling defense against antimicrobial peptides with application to human-pathogenic fungus Candida albicans.NPJ systems biology and applications · 2025Article
- Review
- Breaking Barriers: Candidalysin Disrupts Epithelial Integrity and Induces Inflammation in a Gut-on-Chip Model.Toxins · 2025Article
- Vaginal Candida albicans infections: host-pathogen-microbiome interactions.FEMS microbiology reviews · 2025Review
- The dual role of vulvovaginal candidiasis in HPV infection: implications for vaginal microecology and cervical lesions.Frontiers in microbiology · 2025Review
- Research progress on the application of nanobodies in immunity and infectious skin diseases.Frontiers in immunology · 2025Review
- Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.Cell host & microbe · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Marisa Valentine *Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID 0000-0001-5627-3196
Paul Rudolph *Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID 0000-0002-9494-3303
Axel DietschmannJunior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Antzela TsavouCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, England, United Kingdom.
Selene MogaveroDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Sejeong LeeCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, England, United Kingdom.
Emily L PriestCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, England, United Kingdom.
Gaukhar ZhurgenbayevaInstitute of Applied Optics and Biophysics, Friedrich Schiller University, Jena, Germany.
Nadja JablonowskiDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Sandra TimmeApplied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Christian EggelingInstitute of Applied Optics and Biophysics, Friedrich Schiller University, Jena, Germany.
Stefanie AllertDepartment of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
Edward DolkQVQ B.V, Utrecht, The Netherlands.
Julian R NaglikCentre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, England, United Kingdom.
Marc T FiggeApplied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID 0000-0002-4044-9166
Mark S Gresnigt *Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID 0000-0002-9514-4634
Bernhard Hube *Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.ORCID 0000-0002-6028-0425
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEKing's College London · GBFriedrich Schiller University Jena · DELeibniz Institute of Photonic Technology · DEQserve Group (Netherlands) · NL
Funding
Host and Fungal Regulation of Type 17 Immunity to Oral CandidiasisR37DE022550 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sarah L Gaffen · 2017 to 2026
$5.6MNIDCR NIH HHS R37 DE022550Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
CandidiasisCandidiasis, VulvovaginalFungal ProteinsSingle-Domain AntibodiesCandida albicansFemaleHumansInflammationQuality of LifeECE1 protein, Candida albicansFungal ProteinsSingle-Domain Antibodiescandidalysincytotoxicityinflammationtherapeutic strategyvulvovaginal candidiasis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.